A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

HHS recently terminated a $766 million award to Moderna for developing mRNA vaccines against influenza viruses that run a risk of causing a pandemic, in the midst of an ongoing H5N1 bird flu ...

Moderna's mRNA-based flu vaccine funding is cancelled by the Department of Health and Human Services, arguing lack of scientific and ethical justification.